Athira Pharma Inc

For the period ended Mar 31, 2025. Filed May 9, 2025.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Mar 31, 2025 · Filed May 9, 2025

LONA$4.47+1.2%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Balance Sheets

(in thousands, except share and per share amounts)

	March 31,	December 31,
	2025	2024
(unaudited)
Assets
Current assets:
Cash and cash equivalents	$26,422	$48,438
Short-term investments	10,248	2,837
Prepaid expenses and other current assets	3,183	3,566
Total current assets	39,853	54,841
Restricted cash	631	631
Property and equipment, net	2,201	2,444
Operating lease right-of-use asset	743	808
Other long-term assets	85	55
Total assets	$43,513	$58,779
Liabilities and stockholders' equity
Current liabilities:
Accounts payable	$867	$319
Accrued liabilities	4,199	12,402
Current operating lease liability	426	414
Total current liabilities	5,492	13,135
Operating lease liability, less current portion	691	803
Total liabilities	6,183	13,938
Stockholders' equity:
Common stock, $0.0001 par value; 900,000,000 shares authorized at March 31, 2025 and December 31, 2024, respectively; 39,042,445 and 39,040,945 shares issued and outstanding at March 31, 2025 and December 31, 2024, respectively	4	4
Additional paid-in capital	452,619	450,982
Accumulated other comprehensive (loss) income	(4)	1
Accumulated deficit	(415,289)	(406,146)
Total stockholders' equity	37,330	44,841
Total liabilities and stockholders' equity	$43,513	$58,779

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.